Court document accuses J&J, Bayer of keeping mum about Xarelto lab data

Lawyers suing Johnson & Johnson ($JNJ) and Bayer over alleged injuries from their anticlotting drug Xarelto say that the companies misled editors at The New England Journal of Medicine by failing to speak up about possible discrepancies in patient data from a key trial. The NEJM published a letter, primarily written by Duke University researchers, about the trial, which came under scrutiny last fall because a blood-testing device used in the study had given inaccurate readings. In the letter, the researchers said that readings from the faulty device would not have changed the trial's results. They weren't aware of lab data that might have shed a different light on the device's readings, but the companies were, The New York Times reports. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.